RegisterLogin

Deracoxib

CAT: 0804-HY-17509-01Size: 25 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17509-01Size:25 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas[1][2][3][4][5].
CAS Number
[169590-41-4]
Product Name Alternative
SC 046; SC 46; SC 59046
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; COX
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/deracoxib.html
Purity
99.65
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(N2N=C(C(F)F)C=C2C3=CC=C(OC)C(F)=C3)C=C1)(N)=O
Molecular Formula
C17H14F3N3O3S
Molecular Weight
397.37
Precautions
H302, H315, H319, H335
References & Citations
[1]Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66 (11) : p. 1961-7.|[2]Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740.|[3]Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41 (3) : p. 336-44.|[4]McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239 (8) : p. 1084-9.|[5]Anderson GD, et al. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009 Feb;58 (2) :109-17.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-2

Related Products

CatalogName

Alternative Products

CatalogName
TRC-D281920-100MGDeracoxib
A18077-500Deracoxib 500mg
A18077-50Deracoxib 50mg
TRC-D281922-25MGDeracoxib-d4
A18077-25Deracoxib 25mg
A18077-100Deracoxib 100mg
A18077-200Deracoxib 200mg
A18077-10mM-DDeracoxib 10mM * 1mL in DMSO

Popular Products